{
  "eval_id": "S26",
  "timestamp": "2025-09-19T09:03:28.312332+00:00",
  "model": "gpt-4o",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for HR+/HER2- metastatic breast cancer after at least two prior lines of systemic therapy, including a CDK4/6 inhibitor and endocrine therapy. It’s important to consider patient factors like performance status and any visceral involvement when evaluating its use. For detailed information, please refer to the EMA’s SmPC or EPAR."
}